Identification of fatty acid binding protein 4 as an adipokine that regulates insulin secretion during obesity

Molecular Metabolism

Volumn 3, Issue 4, 2014, Pages 465-473

  Wu, Lindsay E ^a,b   Samocha Bonet, Dorit ^a,b   Whitworth, P Tess ^a   Fazakerley, Daniel J ^a   Turner, Nigel ^a,b   Biden, Trevor J ^a,b   James, David E ^a,c   Cantley, James ^a,b,d  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adipocyte; Adipokine; Beta cell; FABP4; Insulin secretion; Obesity

Indexed keywords

ADIPOCYTOKINE; FATTY ACID BINDING PROTEIN 4;

ADIPOCYTE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL HYPOXIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEEDBACK SYSTEM; FEMALE; GLUCOSE TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEOMICS; SIGNAL TRANSDUCTION;

MUS;

EID: 84902330898     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.02.005     Document Type: Article

References (54)

1. Yach D., Stuckler D., Brownell K.D. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nature Medicine 2006, 12:62-66.
2. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
3. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
4. Alberti K.G.M.M., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome. Circulation 2009, 120:1640-1645.
5. Calle E.E., Thun M.J. Obesity and cancer. Oncogene 2004, 23:6365-6378.
6. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
7. Perley M., Kipnis D.M. Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects. Diabetes 1966, 15:867-874.
8. Polonsky K.S., Given B.D., Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. Journal of Clinical Investigation 1988, 81:442-448.
9. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46:3-19.
10. Winzell M.S., Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004, 53(Suppl.3):S215-219.
11. Latour M., Alquier T., Oseid E., Tremblay C., Jetton T., Luo J., et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion invivo. Diabetes 2007, 56:1087-1094.
12. Karpe F., Dickmann J.R., Frayn K.N. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011, 60:2441-2449.
13. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine 1996, 334:292-295.
14. Kulkarni R.N., Wang Z.L., Wang R.M., Hurley J.D., Smith D.M., Ghatei M.A., et al. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, invivo, in mice. Journal of Clinical Investigation 1997, 100:2729-2736.
15. Winzell M.S., Nogueiras R., Dieguez C., Ahrén B. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochemical and Biophysical Research Communications 2004, 321:154-160.
16. Okamoto M., Ohara-Imaizumi M., Kubota N., Hashimoto S., Eto K., Kanno T., et al. Adiponectin induces insulin secretion invitro and invivo at a low glucose concentration. Diabetologia 2008, 51:827-835.
17. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J.-I., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 1999, 257:79-83.
18. Revollo J.R., Korner A., Mills K.F., Satoh A., Wang T., Garten A., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metabolism 2007, 6:363-375.
19. Jin H., Jiang B., Tang J., Lu W., Wang W., Zhou L., et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Research and Clinical Practice 2008, 79:412-418.
20. Shewan A.M., Marsh B.J., Melvin D.R., Martin S., Gould G.W., James D.E. The cytosolic C-terminus of the glucose transporter GLUT4 contains an acidic cluster endosomal targeting motif distal to the dileucine signal. Biochemical Journal 2000, 350(Pt 1):99-107.
21. Cantley J., Boslem E., Laybutt D.R., Cordery D.V., Pearson G., Carpenter L., et al. Deletion of protein kinase Cdelta in mice modulates stability of inflammatory genes and protects against cytokine-stimulated beta cell death invitro and invivo. Diabetologia 2011, 54:380-389.
22. Ong S.E., Mann M. Apractical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nature Protocols 2006, 1:2650-2660.
23. Humphrey S.J., Yang G., Yang P., Fazakerley D.J., Stockli J., Yang J.Y., et al. Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. Cell Metabolism 2013, 17:1009-1020.
24. Ong S.E., Kratchmarova I., Mann M. Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). Journal of Proteome Research 2003, 2:173-181.
25. Crowe S., Wu L.E., Economou C., Turpin S.M., Matzaris M., Hoehn K.L., et al. Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metabolism 2009, 10:40-47.
26. Bendtsen J.D., Jensen L.J., Blom N., Von Heijne G., Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Engineering, Design & Selection: PEDS 2004, 17:349-356.
27. Turner N., Bruce C.R., Beale S.M., Hoehn K.L., So T., Rolph M.S., et al. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 2007, 56:2085-2092.
28. Hosogai N., Fukuhara A., Oshima K., Miyata Y., Tanaka S., Segawa K., et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56:901-911.
29. Pasarica M., Sereda O.R., Redman L.M., Albarado D.C., Hymel D.T., Roan L.E., et al. Reduced adipose tissue oxygenation in human obesity. Diabetes 2009, 58:718-725.
30. Sun K., Wernstedt Asterholm I., Kusminski C.M., Bueno A.C., Wang Z.V., Pollard J.W., et al. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:5874-5879.
31. Dusaulcy R., Rancoule C., Grès S., Wanecq E., Colom A., Guigné C., et al. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. Journal of Lipid Research 2011, 52:1247-1255.
32. Storch J., Thumser A.E. Tissue-specific functions in the fatty acid-binding protein family. Journal of Biological Chemistry 2010, 285:32679-32683.
33. Hotamisligil G.S., Johnson R.S., Distel R.J., Ellis R., Papaioannou V.E., Spiegelman B.M. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379.
34. Scheja L., Makowski L., Uysal K.T., Wiesbrock S.M., Shimshek D.R., Meyers D.S., et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994.
35. Coe N.R., Simpson M.A., Bernlohr D.A. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. Journal of Lipid Research 1999, 40:967-972.
36. Xu A., Wang Y., Xu J.Y., Stejskal D., Tam S., Zhang J., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clinical Chemistry 2006, 52:405-413.
37. Cao H., Sekiya M., Ertunc M.E., Burak M.F., Mayers J.R., White A., et al. Adipocyte lipid chaperone aP2 is a secreted adipokine regulating hepatic glucose production. Cell Metabolism 2013, 17:768-778.
38. Syamsunarno M.R., Iso T., Hanaoka H., Yamaguchi A., Obokata M., Koitabashi N., et al. Acritical role of fatty acid binding protein 4 and 5 (FABP4/5) in the systemic response to fasting. PLoS One 2013, 8:e79386.
39. Maeda K., Cao H., Kono K., Gorgun C.Z., Furuhashi M., Uysal K.T., et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metabolism 2005, 1:107-119.
40. Wang B., Wood I., Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Archiv European Journal of Physiology 2007, 455:479-492.
41. Tan N.-S., Shaw N.S., Vinckenbosch N., Liu P., Yasmin R., Desvergne B., et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Molecular and Cellular Biology 2002, 22:5114-5127.
42. Gillilan R.E., Ayers S.D., Noy N. Structural basis for activation of fatty acid-binding protein 4. Journal of Molecular Biology 2007, 372:1246-1260.
43. Nauck M.A., Homberger E., Siegel E.G., Alllen R.C., Eatpm R.P., Ebert R., et al. Incretin Effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. Journal of Clinical Endocrinology & Metabolism 1986, 63:492-498.
44. Zhang J., Hupfeld C.J., Taylor S.S., Olefsky J.M., Tsien R.Y. Insulin disrupts beta-adrenergic signalling to protein kinase A in adipocytes. Nature 2005, 437:569-573.
45. Susulic V.S., Frederich R.C., Lawitts J., Tozzo E., Kahn B.B., Harper M.-E., et al. Targeted disruption of the adrenergic receptor gene. Journal of Biological Chemistry 1995, 270:29483-29492.
46. Parkes D.G., Pittner R., Jodka C., Smith P., Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 invivo and invitro. Metabolism 2001, 50:583-589.
47. Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine 2011, 17:1498-1503.
48. Wang B., Wood I.S., Trayhurn P. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes. Journal of Endocrinology 2008, 198:127-134.
49. Tschop M., Strasburger C.J., Topfer M., Hautmann H., Riepl R., Fischer R., et al. Influence of hypobaric hypoxia on leptin levels in men. International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2000, 24(Suppl.2):S151.
50. Nickel W., Seedorf M. Unconventional mechanisms of protein transport to the cell surface of eukaryotic cells. Annual Review of Cell and Developmental Biology 2008, 24:287-308.
51. Frye B.C., Halfter S., Djudjaj S., Muehlenberg P., Weber S., Raffetseder U., et al. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Reports 2009, 10:783-789.
52. Gallagher E.J., LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology 2011, 152:2546-2551.
53. Shanik M.H., Xu Y., Škrha J., Dankner R., Zick Y., Roth J. Insulin resistance and hyperinsulinemia. Diabetes Care 2008, 31:S262-S268.
54. Zimmet P.Z. Hyperinsulinemia - how innocent a bystander?. Diabetes Care 1993, 16(Suppl.3):56-70.